Investing.com - Financial Markets Worldwide
🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

GAVI alliance offers matched funds for GSK malaria vaccine pilot

Published 2016-06-23, 10:57 a/m
© Reuters. GAVI alliance offers matched funds for GSK malaria vaccine pilot
GSK
-

By Kate Kelland, Health and Science Correspondent
LONDON, June 23 (Reuters) - The GAVI global vaccine alliance
has offered funding of up to $27.5 million for pilot tests of
GlaxoSmithKline's GSK.L first-generation malaria vaccine, but
only if other organisations promise to match that commitment.
Evidence so far on the shot, developed by the British
drugmaker with financial backing from the Bill & Melinda Gates
Foundation, "suggests a malaria vaccine could have a significant
impact in reducing malaria mortality in Africa", but more
research is needed, GAVI said.
Speaking to Reuters after a board meeting in Geneva, Seth
Berkley, GAVI's chief executive, said the alliance was ready "to
play its part" in backing the first phase pilot studies if other
funders also came forward. GAVI is working on the issues
alongside UNITAID and the Global Fund, he said.
He added however, that GAVI's board had made clear that this
"should not be considered as an indication of future GAVI
funding" for this vaccine, or for future similar pilot schemes
for other vaccines.
Since the vaccine - known as RTS,S or Mosquirix - is only
partially effective and needs to be given in a four dose
schedule outside normal childhood vaccination plans, experts
have questioned its potential usefulness and cost effectiveness.
The World Health Organization (WHO) said last year that
while Mosquirix is promising, it should be deployed only on a
pilot basis before any wide-scale use, given its limited
efficacy.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.